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ABSTRACT
Hepatocellular carcinoma (HCC) is a highly vascularized tumor with poor 
clinical outcome. Our previous work has shown that eukaryotic initiation factor 5A2 
(EIF5A2) over-expression enhances HCC cell metastasis. In this study, EIF5A2 was 
identified to be an independent risk factor for poor disease-specific survival among 
HCC patients. Both in vitro and in vivo assays indicated that ablation of endogenous 
EIF5A2 inhibited tumor angiogenesis by reducing matrix metalloproteinase 2 (MMP-2) 
expression. Given that MMP-2 degrades collagen IV, a main component of the vascular 
basement membrane (BM), we subsequently investigated the effect of EIF5A2 on 
tumor vasculature remodeling using complementary approaches, including fluorescent 
immunostaining, transmission electron microscopy, tumor perfusion assays and 
tumor hypoxia assays. Taken together, our results indicate that EIF5A2 silencing 
increases tumor vessel wall continuity, increases blood perfusion and improves 
tumor oxygenation. Additionally, we found that ablation of EIF5A2 enhanced the 
chemosensitivity of HCC cells to 5-Fluorouracil (5-FU). Finally, we demonstrated that 
EIF5A2 might exert these functions by enhancing MMP-2 activity via activation of p38 
MAPK and JNK/c-Jun pathways. Conclusion: This study highlights an important role 
of EIF5A2 in HCC tumor vessel remodeling and indicates that EIF5A2 represents a 
potential therapeutic target in the treatment of HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
prevalent and lethal cancers worldwide [1]. In the majority 
of cases, active angiogenesis and a high incidence of 
intrahepatic metastases result in poor survival. HCC 
patients diagnosed at an advanced stage, typically respond 
poorly to traditional therapies as well as to sorafenib, a 
small molecular inhibitor with efficacy against multiple 
tyrosine kinases. Consequently, the clinical treatment of 
HCC remains challenging [2].
In 2001, we isolated a putative oncogene, eukaryotic 
initiation factor 5A2 (eIF5A2), which is located on 
chromosome 3q26, and is frequently amplified in 
multiple human malignancies [3, 4]. Subsequent studies 
have shown that EIF5A2 may play an important role in 
malignant transformation, tumor cell proliferation and 
metastasis [5-8]. Using semi-quantitative RT-PCR and 
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real-time PCR analysis, we demonstrated that EIF5A2 was 
frequently over-expressed in human HCC tumor tissues 
compared to matched healthy counterparts. Moreover, 
compared with matched primary tumor samples, metastatic 
lesions were found to have higher expression of EIF5A2 
by immunohistochemical analysis [6]. Both in vitro and 
in vivo studies demonstrate that EIF5A2 plays a pivotal 
role in promoting HCC cell metastasis by enhancing cell 
motility and invasion, regulating cytoskeletal organization, 
and activating the epithelial-mesenchymal transition 
(EMT) through the Rho/Rac GTPase pathway [6].
Tumor angiogenesis and metastasis are two highly 
interconnected aspects of tumorigenesis. A recent study 
from our colleagues showed that EIF5A2 over-expression 
could promote angiogenesis and metastasis in esophageal 
squamous cell carcinoma [9]. However, the role of EIF5A2 
in HCC angiogenesis remains unclear [10]. In this study, 
both in vitro and in vivo approaches show that silencing of 
endogenous EIF5A2 suppresses angiogenesis induced by 
HCC cells. EIF5A2 silencing was found to remodel tumor 
vasculature, increase blood perfusion and sensitize tumor 
cells to chemotherapeutic agents. In addition, this study 
sheds light on the molecular mechanisms underlying the 
effects of EIF5A2 on tumor angiogenesis and vasculature 
remodeling.
RESULTS
Silencing endogenous EIF5A2 inhibits HCC 
angiogenesis.
To determine whether EIF5A2 dysregulation could 
affect angiogenesis in human HCC, an in vitro capillary 
tube formation assay was employed in PLC8024 and 
Huh7 HCC cell lines, both of which express high levels 
of EIF5A2 (Fig. 1A). Endogenous EIF5A2 in Huh7 
and PLC8024 cells was silenced through expression of 
EIF5A2 specific shRNAs. Four independent shRNAs 
specifically reduced expression of endogenous EIF5A2 in 
both HCC cell lines (Fig. 1B). Given its comparatively 
high efficiency of EIF5A2 knockdown, sh#2 and sh#3 was 
chosen for subsequent studies. Tumor cell-conditioned 
medium (TCM) from cells transfected with NC, sh#2 or 
sh#3 was used to supplement the culture medium in which 
for human umbilical vein endothelial cells (HUVECs) 
were grown. As shown in Fig.1C, EIF5A2 inhibition 
suppressed the ability of HCC cells to induce formation 
of capillary-like structures. In order to further confirm the 
impact of EIF5A2 on tumor angiogenesis, we injected 
nude mice subcutaneously with PLC8024 cells stably 
expressing either sh#2 or sh#3 against EIF5A2 or NC. 
Compared with the control group, the EIF5A2 knockdown 
group showed lower micro-vessel density (MVD) as 
determined by CD34 immunostaining of tumor sample 
sections (Fig. 1D). Of note, the tumor growth curves of 
both groups showed that ablation of endogenous EIF5A2 
did not significantly impact tumor cell growth, suggesting 
that the inhibitory function of EIF5A2 silencing on 
angiogenesis may not be resulted from tumor growth 
inhibition (Supplementary Fig. 1).
MMP2 mediates the effect of EIF5A2 on 
angiogenesis.
We next explored the underlying molecular 
mechanisms responsible for the effects of EIF5A2 on 
angiogenesis. Based on our previous study as well as 
previously published reports, we used real-time RT-
PCR to screen the molecular markers closely related 
with angiogenesis in HCC [10]. As shown in Fig. 2A, 
MMP-2 was significantly downregulated at the 
transcript level in both PLC8024-sh#3 and Huh7 sh#3 
cell lines, while other angiogenesis markers exhibited 
only slight changes in response to EIF5A2 suppression. 
Furthermore, gelatin zymography demonstrated that, 
compared with TCM obtained from control cells, 
TCM from PLC8024-sh#2 or sh#3 and Huh7-sh#2 
or sh#3 exhibited a significant reduction in MMP-2 
activity (Fig. 2B). Consistent with these results, ectopic 
EIF5A2 expression in SMMC7721 cells enhanced 
MMP-2 activity (Fig. 2B). Furthermore, compared 
with PLC8024-NC group, xenografts tumors of 
PLC8024-sh#2 or sh#3 also showed decreased MMP-2 
expression analyzed by IHC (Fig. 2C). To investigate 
the requirement for MMP2 in angiogenesis induced 
by EIF5A2, we employed an MMP-2 blocking assay. 
As expected, treatment of SMMC7721-EIF5A2 cells 
with MMP-2 neutralizing antibody (final concentration: 
6μg/ml) attenuated the pro-angiogenic effect of EIF5A2 
(Fig. 2D). Additionally, MMP2 over-expression in 
PLC8024-sh#3 cells rescued the effect of EIF5A2 on 
angiogenesis (Fig. 2E). These data indicate that MMP2 
is necessary for EIF5A2-induced angiogenesis.
Immunoreactivity for EIF5A2 was examined 
primarily in the cytoplasm of tumor cells. The nuclear 
expression of EIF5A2 was also observed in 36 
(36/212) HCC cases. The association between EIF5A2 
expression and either MMP2 expression or angiogenesis 
in 212 HCC patients were further assessed using 
immunohistochemistry on a tissue micro-array (TMA) 
platform, which demonstrated that EIF5A2 expression 
was significantly associated with MMP-2 expression 
as well as MVD (P=0.022 and P=0.030) (Table. 1 and 
Fig. 3A). Based on the X-tile analysis, the cut-point 
for high expression of EIF5A2 was defined when the 
H scores were above 150. Further correlation analysis 
showed that EIF5A2 over-expression in HCCs was 
significantly associated with tumor multiplicity and stage 
(P<0.05, Table 1). Kaplan–Meier analysis established 
that patients with high EIF5A2 expression had poorer 
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Figure 1: EIF5A2 downregulation represses tumor angiogenesis. (A, B) Immunoblot analysis of indicated proteins in HCC cell 
lines. (C) EIF5A2 ablation inhibited tube formation of HUVECs induced by HCC cells. Representative images (100x) and quantification 
of HUVECs cultured on Matrigel-coated plates with 75% conditioned medium from the indicated cell transfected with NC or shRNA-
EIF5A2. (D) EIF5A2 ablation inhibited tumor angiogenesis in a xenograft model. Sections of tumor tissues derived from PLC8024-NC 
or PLC8024sh#2 or sh#3 xenografts were stained for EIF5A2 and mouse CD34 by IHC. The three most intensely vascularized areas were 
evaluated under light microscopy. Representative images (100x) and the quantitative MVD measurement of two groups are presented 
(*, P<0.05).
disease-specific survival compared to those with low 
EIF5A2 expression (Log-rank test, P<0.001) (Table 2 and 
Fig. 3B). Multivariate Cox regression analysis identified 
EIF5A2 expression as an independent risk factor for poor 
disease-specific survival of HCC patients, with a hazard 
ratio (HR) of 1.522 (95% confidence interval [CI]: 1.065-
2.175) (P=0.021) (Table 3). Moreover, transwell assay 
indicated that MMP2 was also involved in the inducible 
effect of EIF5A2 on tumor invasion (Supplementary 
Fig. 2). Taken together, these findings suggest that EIF5A2 
overexpression may promote angiogenesis and invasion of 
HCC by enhancing MMP2 activity.
Silencing endogenous EIF5A2 promotes tumor 
vascular normalization.
Blood vessels are comprised of basement 
membranes (BMs), pericytes and vascular endothelial 
cells. Vascular BM components are required for the 
initiation and resolution of angiogenesis [11]. Since 
type IV collagen, a substrate for MMP-2 and the 
main component of the vascular BM, is crucial for 
BM stability and assembly [12, 13]. We hypothesized 
that EIF5A2 may also affect tumor blood vessel 
wall remodeling or vessel structure via regulation of 
MMP-2 activity. Collagen IV and CD34 expression were 
examined by immunofluorescent staining of xenograft 
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Figure 2: MMP-2 is required for EIF5A2-induced angiogenesis in HCC. (A) Changes in mRNA expression of the indicated genes 
in two EIF5A2-suppressed HCC cell lines were assessed by real-time qPCR. (B) Analysis of MMP-2 activity in TCM by gelatin zymography. 
TCM was collected from tumor cells transfected with NC or shRNA-EIF5A2 or with control vector or eIF5A2 over-expression vector. 
Recombinant human MMP2 (rHuMMP2) as the positive control. (C) Analysis of MMP-2 expression in xenograft tumor tissue sections. 
(D) Inhibition of MMP-2 (final concentration of anti-MMP2 antibody: 6ug/ml) repressed the pro-angiogenic effect of EIF5A2 over-
expression in SMMC7721 cells. (E) Re-expression of MMP-2 in EIF5A2 knockdown PLC8024 cells restored the pro-angiogenic effect of 
EIF5A2.
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Table 1. Correlation of IEF5A2 expression with patients’ clinicopathological features in primary 
hepatocellular carcinomas
Variable EIF5A2 protein
All cases Low expression High expression P value1
Age (years) 0.266
 ≤ 47.92 105 65 (61.9%) 40 (38.1%)
 > 47.9 107 74 (69.2%) 33 (30.8%)
Sex 0.432
 Female 38 27 (71.1%) 11 (28.9%)
 Male 174 112 (64.4%) 62 (35.6%)
HbsAg 0.611
 Negative 48 30 (62.5%) 18 (37.5%)
 Positive 164 109 (66.5%) 55 (33.5%)
AFP (ng/ml) 0.773
 ≤20 67 43 (64.2%) 24 (35.8%)
 >20 145 96 (66.2%) 49 (33.8%)
Liver cirrhosis 0.665
 No 80 51 (63.8%) 29 (36.3%)
 Yes 132 88 (66.7%) 44 (33.3%)
Tumor size (cm) 0.042
 ≤5 59 45 (76.3%) 14 (23.7%)
 >5 153 94 (61.4%) 59 (38.6%)
Tumor multiplicity 0.017
 Single 128 92 (71.9%) 36 (28.1%)
 Multiple 84 47 (56.0%) 37 (44.0%)
Differentiation 0.285
 Well-moderate 153 97 (63.4%) 56 (36.6%)
 Poor-undifferentiated 59 42 (71.2%) 17 (28.8%)
Stage 0.032
 I-II 88 66 (73.9%) 23 (26.1%)
 III- IV 124 74 (59.7%) 50 (40.3%)
Vascular invasion 0.164
 Absent 104 73 (70.2%) 31 (29.8%)
 Present 108 66 (61.1%) 42 (38.9%)
Relapse 0.362
 Absent 107 67 (62.6%) 40 (37.4%)
 Present 105 72 (68.6%) 33 (31.4%)
MMP2 0.022
 Low expression 55 43 (78.2%) 12 (21.8%)
 High expression 157 96 (61.1%) 61 (38.9%)
(continued)
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Variable EIF5A2 protein
All cases Low expression High expression P value1
MVD 0.030
 ≤79 126 90 (71.4%) 36 (28.6%)
 >79 86 49 (57.0%) 37 (43.0%)
1Chi-square test;
2Mean age.
Figure 3: Association among expression of EIF5A2, MMP-2, MVD and its prognostic significance in HCC 
patients. (A) Representative images of IHC staining for EIF5A2, MMP-2 and CD34 in two HCC cases (100x). EIF5A2 expression 
positively correlated with MMP-2 expression and tumor MVD. (B) X-tile analysis was employed to determine the cut-point for EIF5A2 
expression in HCC. The cut-point (H score=150) highlighted by the black/white circle in the horizontal axis (left panel) was demonstrated 
on a histogram of the cohort (middle panel), and a Kaplan-Meier plot (right panel).
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Table 2. Univariate analysis of EIF5A2 expression and clinicopathologic variables in 212 patients 
with primary hepatocellular carcinoma (log-rank test)
Variables All cases RR (95% CI) P value
Age (years) 0.627
≤ 47.9 105 1.0
> 47.9 107 1.090 (0.770-1.542)
Sex 0.045
Female 38 1.0
Male 174 1.650 (1.012-2.688)
HbsAg 0.810
Negative 48 1.0
Positive 164 1.053 (0.692-1.602)
AFP (ng/ml) 0.000
≤20 67 1.0
>20 145 2.262 (1.490-3.434)
Liver cirrhosis 0.891
No 80 0.975 (0.682-1.395)
Yes 132 1.0
Tumor size (cm) 0.000
≤5 59 1.0
>5 153 6.295 (3.688-10.747)
Tumor multiplicity 0.000
Single 128 1.0
Multiple 84 3.480 (2.429-4.987)
Differentiation 0.021
Well-moderate 153 1.0
Poor-undifferentiated 59 1.534 (1.068-2.203)
Stage 0.000
I-II 88 1.0
III- IV 124 5.393 (3.525-8.252)
Vascular invasion 0.000
Absent 104 1.0
Present 108 4.923 (3.310-7.322)
Relapse 0.000
Absent 107 1.0
Present 105 1.907 (1.330-2.734)
EIF5A2 expression 0.000
 Low 139 1.0
High 73 1.914 (1.350-2.714)
CI, confidence interval; HbsAg, hepatitis B surface antigen; AFP, alpha-fetoprotein.
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tissue sections. Compared with the control group, tumor 
micro-vessels in xenografts from EIF5A2 knockdown 
tumor cells exhibit more continuous and smooth wall, 
more regular endothelial lining, and morphology similar 
to normal vasculature (Fig. 4A). Similarly, vessel walls 
in EIF5A2 and MMP2 low expression human HCC tissue 
sections were more continuous (Fig. 4B, Supplementary 
Fig. 3). Transmission electron microscopy further revealed 
that the vessels in the EIF5A2 knockdown group were 
more likely to have continuous BMs, well differentiated 
endothelial cells, and same polarity in their endothelial 
linings (Fig. 4C). These data suggest that EIF5A2 ablation 
could induce formation of integrated, continuous vascular 
walls and normalized endothelial cells lining. Moreover, 
transmission electron microscopy indicated that the 
micro-vessels in EIF5A2 knockdown group displayed 
larger lumens and thinner walls which may enhance blood 
perfusion and facilitate nutrient and oxygen exchange.
Downregulation of EIF5A2 increases tumor 
perfusion and response to chemotherapy.
We further assessed the effect of EIF5A2 ablation on 
blood perfusion and the tumor microenvironment. Tumor 
blood vessel flow, as measured by laser Doppler imaging, 
was significantly increased in the EIF5A2-silenced group 
compared to the NC control group (Fig.5A). To further 
examine intratumoral blood perfusion and leakage, a 
mouse model was created by injecting FITC-Lectin 
and Dextran into the tail vein of tumor bearing nude 
mice. Fluorescent immunostaining of tumor sections 
indicated that EIF5A2 downregulation increased tumor 
perfusion while reducing blood leakage (Fig. 5B). Since 
supplying oxygen is an ancestral function of vessels, 
we hypothesized that EIF5A2 inhibition would improve 
tumor oxygenation. IHC staining of the hypoxia-
marker pimonidazole revealed a reduction in hypoxia 
in PLC8024-sh#3 cells (Fig. 5C). We then investigated 
whether endogenous EIF5A2 ablation could increase 
the sensitivity of HCC cells to chemotherapy. Twelve 
nude mice were injected subcutaneously with either 
PLC8024-NC (n=6) or PLC8024-sh#3 (n=6) cells. When 
the xenograft tumors reached ~5 mm3 in size, mice were 
injected intraperitoneally with 5-FU (40 mg/kg body 
weight once per week for 5 weeks). In comparison with 
the PLC8024-NC group, tumor growth rates and tumor 
volumes were significantly reduced in the PLC8024-sh#3 
group (p<0.05, Fig. 5D and 5E). These data suggested that 
silencing of endogenous EIF5A2 expression could reduce 
tumor hypoxia, thus increase the chemosensitivity to 5-FU 
by remodeling tumor vessels.
EIF5A2 regulates MMP2 by activating p38 
MAPK and JNK/c-Jun pathway.
To further explore the mechanisms by which 
EIF5A2 regulates MMP-2 activity, we evaluated the 
effects of EIF5A2 knockdown or over-expression on 
the activation of signal transduction pathways. The 
MAPK signaling pathway regulates MMP2 expression 
depending on cellular context, and is mediated by p38 
MAPK, ERK1/2, and JNK/c-Jun [14-17]. In agreement 
with previous findings, our study showed that the 
levels of phosphorylated ERK1/2 and p38 MAPK were 
dramatically decreased in both EIF5A2-silenced PLC8024 
and Huh7 cells, but increased in EIF5A2-overexpressing 
SMMC7721 cells (Fig. 6A). Interestingly, phosphorylated 
JNK and c-Jun were also significantly decreased in 
EIF5A2-silenced PLC8024 cells, but only slight changes 
were observed in EIF5A2-silenced Huh7 and SMMC7721 
cells ectopically expressing EIF5A2 (Fig. 6A). However, 
phosphorylated Akt levels remained unchanged in 
regardless of EIF5A2 expression. To further explore 
the role of p38 MAPK and ERK1/2 in the induction of 
MMP-2 activity by EIF5A2, siRNAs targeting to p38 
MAPK and ERK1/2 were transfected into the EIF5A2-
expressing SMMC7721 cells. MMP-2 activity in the 
EIF5A2-transfected SMMC7721 cells was shown to be 
Table 3. Cox multivariate analyses of prognostic factors on disease-specific survival.
Variables Hazards ratio 95% CI P value
AFP, ng/ml (≤20 v >20) 1.341 0.876-2.054 0.177
Tumor size, cm (≤5 v >5) 2.138 1.158-3.945 0.015
Tumor multiplicity (single v multiple) 2.005 1.381-2.911 0.000
Differentiation(well-moderate v poor-undifferentiated) 1.453 0.995-2.123 0.053
Stage (I-II v III-IV) 2.391 1.455-3.930 0.001
Vascular invasion (absent v present) 2.199 1.427-3.388 0.000
Relapse (absent v present) 1.318 0.902-1.926 0.154
EIF5A2 expression (low v high) 1.522 1.065-2.175 0.021
CI, confidence interval; AFP, alpha-fetoprotein.
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Figure 4: EIF5A2 ablation increases micro-vessel wall continuity and promotes normal endothelial cell lining and 
differentiation. (A) Xenograft tumor sections stained for CD34 (green) and collagen IV (red) revealed more continuous BMs in EIF5A2- 
ablation cells compared to control cells. (B) Representative images of human HCC tissue sections stained for CD34 and collagen IV by 
IF (400x). Twenty cases (10 with high EIF5A2 and MMP-2 expression and 10 with low EIF5A2 and MMP-2 expression), were analyzed 
for tumor vessel wall continuity by IF. Increased continuity of vessel walls was seen in all cases with low EIF5A2 and MMP-2 expression. 
For A and B, the three most intensely vascularized areas were evaluated under immunofluorescence microscopy. (C) Transmission electron 
microscopy of vessels in tumors derived from PLC8024 cells transfected with NC or sh#3. Left column, arrowheads indicate red blood 
cell. Compared with NC group, endothelial cells in the EIF5A2 knockdown group were lined with more continuous BMs (right column, 
arrowhead). For the NC group, left column, original magnification 5800x; right column, 13500x. For sh#3 group, left column, original 
magnification 2400x; right column, 13500x.
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Figure 5: EIF5A2 ablation increases tumor blood perfusion, reduces tumor hypoxia and enhances sensitivity to 
chemotherapy. (A) Representative images of Doppler laser imaging of intratumoral blood flow. Left side: Doppler imaging; Right 
side: the corresponding position of the Doppler imaging on the mice. The mean value of the blood flow is the mean number of the blood 
flow of six tumors in one group mice. Bar graphs show quantification of corresponding perfusions. P=0.011. (B) Increased tumor vessel 
perfusion and reduced vessel leakiness in the PLC8024-sh#3 group following injection with Texas Red-conjugated Dextran (red) and 
FITC-conjugated Lectin (green). White arrowheads on merged images indicated sites of leakage. (C) Reduced staining for pimonidazole 
in tumors derived from PLC8024 cells transfected with NC or sh#3. Arrowheads indicated necrosis regions. Cells peripheral to necrotic 
areas were stained most intensely, indicating severe hypoxia. (D) EIF5A2 silencing sensitizes xenografts to 5-fluorouracil. Representative 
images of xenograft tumors induced by PLC8024-NC or PLC8024-sh#3 in nude mice. Left column, before treatment; middle column, 
5 weeks after treatment with 5-FU (intraperitoneal injection, 40mg/kg body weight, once weekly for 5 weeks); right column, representative 
tumors excised from mice after 5 weeks of treatment. E. Tumor growth curves (N=6 mice per group); tumor volumes were measured on a 
weekly basis.
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Figure 6: EIF5A2 induces MMP-2 transcription by activating p38 MAPK and JNK/c-Jun pathways. (A) Immunoblot for 
indicated mediators of MAPK pathway signaling in cells transfected with NC or sh#3 or control vector or EIF5A2 over-expression vector. 
(B) MMP-2 activity in TCM examined by gelatin zymography. TCM was collected from cells transfected with NC or si-RNA targeting p38 
MAPK or ERK1/2. (C) Analysis of luciferase activity using MMP-2 promoter luciferase reporter vector in indicated cells. Basic: pGL3-
basic; WT: wild type promoter; ∆AP-1: deletion of AP-1 binding site (**, P<0.01; *, P<0.05, T test).
decreased by siRNAs against p38 MAPK but not ERK1/2 
(Fig. 6B). To examine whether the c-Jun participates in 
the induction of MMP-2 activity by EIF5A2, luciferase 
reporter vector containing the wild-type MMP-2 promoter 
and a deletion mutation of AP-1 binding site within the 
MMP-2 promoter (∆AP-1-MMP-2) were transiently co-
transfected with pRL-TK into PLC8024-NC and sh#3 cells 
or co-transfected with vector or EIF5A2 over-expression 
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vector into SMMC7721 cells [18]. In contrast to the 
wild-type promoter reporter, the luciferase activity of 
∆AP-1-MMP-2 was unchanged between PLC8024-
NC and sh#3 cells (Fig. 6C). However, in SMMC7721 
cells, EIF5A2 over-expression enhanced luciferase 
activity driven by the deletion mutant promoter 
(Fig. 6C). Moreover, the deletion of the AP-1 binding site 
significantly reduced reporter activity in both cell lines, 
which indicates that AP-1 is an important regulatory 
factor for MMP-2 activity (Fig. 6C). Taken together, these 
results indicated that the stimulation of MMP-2 by the 
EIF5A2 signaling pathway depended on specific cellular 
contexts. To further explore whether EIF5A2 regulates 
MMP-2 expression primarily at the transcriptional level, 
the MMP-2 3’-UTR (untranslated region) was cloned 
into the pMIR-REPORT luciferase reporter vector. Dual-
luciferase reporter analysis showed that EIF5A2 silencing 
did not alter the activity of the MMP2 3’-UTR luciferase 
reporter, indicating that EIF5A2 may regulate MMP-2 
gene expression by enhancing binding of transcription 
factors binding such as AP-1 at the MMP-2 promoter 
(Supplementary Fig. 4). However, the roles of other 
potential transcriptional factors in the induction of MMP2 
by EIF5A2 still warrant further evaluation.
DISCUSSION
HCC is a highly vascularized tumor that frequently 
undergoes intrahepatic metastasis [10]. Despite the 
development of multimodality treatment approaches, 
including surgical resection, chemotherapy, radiotherapy, 
as well as the molecular targeted therapies, the outcome 
of HCC patients remains poor. Therefore, it is urgent to 
further define the key molecular mechanisms driving 
HCC progression and identify new targets for the 
treatment of HCC. In this study, we show for the first 
time that the ablation of endogenous EIF5A2 can improve 
tumor oxygenation and sensitizes to chemotherapy by 
remodeling tumor vasculature. We also demonstrated that 
EIF5A2 may exert these functions by enhancing MMP-2 
activity via activation of the MAPK pathways.
Since angiogenesis is essential for tumor 
growth, development of antiangiogenic therapies 
to suppress tumor progression is an area of intense 
research focus [19, 20]. In this study, the influences 
of EIF5A2 on angiogenesis, vascular structure, vessel 
function and tumor microenvironment in HCC were 
evaluated using both in vitro and in vivo approaches. 
Immunohistochemical staining of CD34 showed that 
silencing endogenous EIF5A2 could reduce tumor MVD, 
a marker for angiogenesis. Consistent with the role of 
EIF5A2 in melanoma [21], functional studies as well as 
the clinical data indicate that EIF5A2 over-expression 
in HCC can promote tumor angiogenesis and tumor cell 
invasion. Accumulating evidences show that MMPs 
play an important role in tumor invasion, metastasis and 
angiogenesis. However, MMP2, MMP9 and MMP14 
[22] are the three major MMPs reported to be involved in 
tumor angiogenesis. Therefore, we tested the RNA levels 
of MMP2, MMP9 and MMP14 in EIF5A2 ablation cell 
lines to explore whether they take part in the regulation 
of HCC angiogenesis by EIF5A2. Previous studies also 
reported that MMP14 promoter’s transcriptional activity 
could be regulated by SP1, NFAT1c and Egr-19 [23, 24], 
while the expression of MMP2 and MMP9 were mediated 
by cytokines via activation of transcription factors (TFs) 
such as AP-1, which can be regulated by MAPK signaling. 
However, MMP-2 was found to be an essential molecule 
in determining endothelial cell (EC) fate, paradoxical 
effects on both angiogenesis and cell death. Two major 
apoptotic pathways in ECs, caspases and p38 MAPK, 
enhance MMP-2 synthesis and affect EC behavior via 
different activation form of MMP-2 [25, 26]. Our data 
did show that MMP2 but not MMP9 and MMP14 level 
was significantly changed in EIF5A2 ablation cells. 
Taken together, these evidence may at least partly support 
that MMP2 is selectively involved in EIF5A2-related 
mechanism, but no for MMP9 and MMP14. Nonetheless, 
the underlying mechanism by which EIF5A2 regulates 
MMPs requires further investigation.
Collagen IV, the main component of the vascular 
BMs and the substrate of MMP-2, is important for BM 
integrity and structural organization. BMs are essential 
for proper endothelium organization, migration and 
proliferation [27]. Therefore, we examined the effect 
of EIF5A2 silencing on tumor vessel wall remodeling, 
vascular function and tumor microenvironment. CD34 
and collagen IV co-staining of xenograft tissue sections 
and human HCC tissue sections demonstrated that tumor 
vessel walls in the EIF5A2 low expression group were 
more smooth and continuous. Transmission electron 
microscopy further verified that EIF5A2 ablation induced 
well-differentiated phenotype in endothelial cells. BMs 
function provides a supporting substratum for epithelial 
sheets and maintain cell polarity in epithelia [27]. 
Consistent with these findings, our results indicated that 
continuous vascular BMs might also provide a supporting 
scaffold for endothelial cell lining and differentiation, 
which in turn makes vascular walls thinner and facilitates 
material exchange of oxygen and nutrients. Furthermore, 
we found that EIF5A2 silencing could increase blood 
perfusion, reduce tumor hypoxia and thus improve the 
sensitivity to chemotherapy.
Despite significant inhibition of tumor angiogenesis 
by EIF5A2 ablation, obvious suppression of liver tumor 
growth was not observed in this study, indicating that agent 
targeting angiogenesis itself may not be able to sufficiently 
inhibit tumor growth. Consistent with our findings, recent 
clinical data showed that traditional antiangiogenic agents 
may have limited efficacy in the treatment of cancer, with 
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only minimal improvements in overall patient’s survival 
[28]. To investigate the discrepancies between initial 
predictions and the clinical data, Conley and colleagues 
demonstrated that the antiangiogenic agents might enrich 
the population of breast cancer stem cells by generating 
intratumoral hypoxia [29]. Studies by Mazzone et al. using 
transgenic mouse model demonstrated that endothelial 
lining normalization and vessel maturation could improve 
tumor perfusion and oxygenation, inhibiting tumor 
cell metastasis and thus improving tumor response to 
chemotherapy [30, 31]. These findings suggest that 
potential effects on tumor vasculature structure, function 
and tumor microenvironment should be considered in the 
design and development of new antiangiogenic agents. 
Taken together with the findings presents here, these data 
strongly suggest EIF5A2 is a promising molecular target 
for anti-HCC therapy.
We further investigated the underlying mechanisms 
by which EIF5A2 regulated MMP-2 activity. Luciferase 
reporter assays and siRNA specifically targeting MAPK 
pathway mediators showed that EIF5A2 could promote 
MMP-2 activity by activating the JNK/c-Jun and p38 
MAPK pathway. We also found that EIF5A2 ablation or 
over-expression had no significant effect on the expression 
of TIMP2, the natural inhibitor of MMP2 (Data not 
shown). Fang et al. found that miR-29b could suppress 
tumor angiogenesis and metastasis by directly targeting 
MMP-2 [32]. Luciferase reporter gene assays showed that 
EIF5A2 regulates MMP-2 primarily at the transcriptional 
level through its promoter activity but not its 3’UTR, 
indicating that microRNAs do not play an essential role in 
the interplay between EIF5A2 and MMP2 in HCC.
Tumor blood vessels are characterized by distorted 
vessel shape, capillary sprouting, lack of proper pericyte 
coverage and leakiness, which facilitate extravagation of 
tumor cells [19]. Our previous study showed that EIF5A2 
could promote HCC cell metastasis by inducing tumor cell 
EMT. The data presented in this study suggested that EIF5A2 
deregulation may play a vital role in tumor angiogenesis, 
remodeling of vascular structure and chemotherapy 
sensitivity of HCC. Recent other studies also showed that 
EIF5A2 play an important role in chemoresistance in breast 
cancer and promote bladder cancer cell aggressiveness 
[33-35]. Taken together, ablation of EIF5A2 may represent 
a promising anti-cancer strategy, targeting the crossroads of 
angiogenesis and metastasis in HCC.
MATERIALS AND METHODS
Patients and tissue microarray (TMA).
Formalin-fixed, paraffin-embedded tissues of 212 
HCC patients, who underwent initial surgical resection 
between March 2003 and August 2006, were obtained 
from the archives of the Department of Pathology of 
the First Affiliated Hospital, Sun Yat-sen University 
(Guangzhou, China). Clinicopathological characteristics 
for the HCC cohort were detailed in Table 1. Tumor 
differentiation was determined based on the criteria 
proposed by Edmonson and Steiner [36]. Tumor stage was 
defined according to the tumor-node-metastasis (TNM) 
classification system from the American Joint Committee 
on Cancer/International Union Against Cancer [37]. The 
Institute Research Medical Ethics Committee of Sun Yat-
sen University granted approval for this study.
TMAs were constructed in accordance with a 
previously-described method [38].
Cell lines.
Six HCC cell lines (SMMC-7721, Hep3B, 
PLC8024, Huh7 BEL7402 and HepG2) were selected and 
cultured in this study. All HCC cell lines and immortalized 
human liver cells LO2 were cultured in high-glucose 
DMEM (Gibco BRL, Grand Island, NY) supplemented 
with 10% fetal bovine serum. Human umbilical vein 
endothelial cells (HUVECs) was a generous gift from 
Dr Li-bing Song (Sun Yat-sen University Cancer Center, 
Guangzhou, China) [39]. HUVECs were cultured as 
previously described [34]. Primary HUVECs were used at 
passages 2-7 in all experiments.
Quantitative real-time RT-PCR (qRT-PCR) and 
western blot.
Real-time RT-PCR was performed using an ABI 
PRISM 7500 Sequence Detection System (Applied 
Biosystems) with 2x SYBR green master mix (Applied 
Biosystems, Foster City, CA) using the 2-Δ ΔCT method. 
qRT-PCR primers are listed in Table 4. Western blotting 
was performed according to standard protocols with 
antibodies for AKT (cat.2920, Cell Signaling Technology, 
Beverly, MA) , phospho-ser473-AKT (cat.4060, CST), 
ERK1/2 (cat.4696, CST), phosphor-T202/ Y204-
ERK1/2 (cat.4370, CST), p38 MAPK (cat.9212, CST), 
phospho-T180/Y182-p38 MAPK (cat.4511, CST), 
SAPK/JNK (cat.9268, CST) and phospho-T183/Y185-
SAPK/JNK (cat.4668, CST), MMP-2 (cat.10373-2-AP, 
Proteintech Group, Chicago, USA), phospho-S63-cJun 
(cat. ab32385, Abcam, USA) and GAPDH (cat. BM1985, 
Boster, Wuhan, China).
RNA oligonucleotides and vectors.
Small interfering RNA (siRNA) duplexes specific for 
p38 MAPK and MMP2 were purchased from Genepharma 
(Shanghai, China), and siRNA specific for ERK1/2 were 
purchased from Cell Signaling (Beverly, MA). The 
negative control RNA duplex (NC) for siRNA was not 
homologous to any human genome sequence.
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Table 4. Primer sequences used for qRT-PCR.
Name Sequence
ANG1-F 5’-ATGGACTGGGAAGGGAACCGAGC-3’
ANG1-R 5’-GGGGCCACAAGCATCAAACCACC-3’
ANG2-F 5’-TAAGCAGCATCAGCCAACCAGGAAA-3’
ANG2-R 5’-TTTGTGTTCTGCCTCTGTGGATAGTA-3’
VEGFA-F 5’-CCTGTGTGCCCCTGATGCGATG-3’
VEGFA-R 5’-GCTTTCGTTTTTGCCCCTTTCCCT-3’
HIF1A-F 5’-GCACAGAAGCAAAGAACCCATTTTC-3’
HIF1A-R 5’-GGCAGTGGTAGTGGTGGCATTAG-3’
EGF-F 5’-TGCCAGCTGCACAAATACAGAGGG-3’
EGF-R 5’-CATCGTGGGACAGGGGACATTCA-3’
PD-ECGF-F 5’-TCCTGCGGACGGAATCC-3’
PD-ECGF-R 5’-TGAGAATGGAGGCTGTGATGAG-3’
MMP2-F 5’-CTTCCAAGTCTGGAGCGATGT-3’
MMP2-R 5’-TACCGTCAAAGGGGTATCCAT-3’
MMP9-F 5’-GGGACGCAGACATCGTCATC-3’
MMP9-R 5’-TCGTCATCGTCGAAATGGGC-3’
MMP14-F 5’- GGAATAACCAAGTGATGGATGG-3’
MMP14-R 5’- TTGTTTCCACGGAAGAAGTAGG-3’
GAPDH-F 5’-CATGAGAAGTATGACAACAGCCT-3’
GAPDH-R 5’-AGTCCTTCCACGATACCAAAGT-3’
Vectors: EIF5A2 specific shRNA vectors were 
purchased from Sigma. pcDNA3.1-EIF5A2 was 
constructed as previously described [7]. MMP2 cDNA, 
purchased from GeneCopoeia Inc, was cloned into 
pcDNA3.1(+). Firefly luciferase reporter plasmids pGL3-
MMP2-promoter-wild-type (WT) and pGL3-MMP2-
∆AP-1 contained wild-type and an AP-1 binding site 
(-1242 ~ -1239) deletion mutation of human MMP2 
promoter, respectively. The wild type 3’-UTR segment of 
human MMP2 mRNA was cloned into the pMIR-REPORT 
luciferase reporter vector. The constructs was prepared 
according to standard clone protocol. The primers used 
for cloning are listed in Table 5.
Lentivirus production and transduction.
Virus particles were harvested 48 h after shRNA 
specific for human EIF5A2 was transfected with the 
packaging plasmid pRSV/pREV, pCMV/pVSVG and 
pMDLG/pRRE into 293FTcells using Lipofectamine 
2000 (Invitrogen). PLC8024 and Huh7 cells were 
infected with recombinant lentivirus-transducing units 
supplemented with 8 mg/ml Polybrene (Sigma, St Louis, 
Missouri, USA).
Cell transfections.
pcDNA3.1-EIF5A2 or the control plasmid 
pcDNA3.1(+) or short interfering RNAs (25nM) 
were transfected into HCC cells in 6-well plates using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) 
according to the manufacturer’s instructions. The 
efficiency of transfection was measured by western 
blotting or gelatin zymography 48 h post-transfection.
Cell invasion assay.
The transwell cell invasion assay was performed in 
BD BioCoat Matrigel Invasion Chambers (Becton Dickinson 
Labware, Franklin Lakes, NJ) with 8μm pores according 
to the manufacturer’s instructions. Briefly, 36 hours after 
transfection with RNA duplexes, 2×105 tumor cells diluted 
in 100μl serum-free medium were added to the upper 
compartment of the chamber, while the lower compartment 
was filled with 500μl of DMEM containing 10% FBS. After 
24 h, the non-invading cells were gently removed with 
a cotton swab. Invasive cells located on the lower side of 
the chamber were stained with crystal violet, air dried and 
photographed. Experiments were performed 3 times.
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Preparation of tumor cell-conditioned medium 
(TCM).
Liver tumor cells were first incubated in serum-
free medium for 24h. Then, TCM was collected and 
centrifuged to remove cell debris. TCM was then stored in 
aliquots at -80ºC until used. Each corresponding well was 
subsequently trypsinized and the number of live cells was 
counted to allow appropriate correction of TCM loading. 
For the MMP-2 blocking assay, TCM was preincubated 
with an MMP-2-neutralizing antibody (ab80737, Abcam) 
or an isotype-matched control immunoglobulin G (IgG) 
(Boster, Wuhan, China) for 1 hour at 37ºC, before being 
applied to the HUVEC coculture.
Capillary tube formation assay.
HUVECs were cultured in the absence or presence 
of 75% TCM for 10 hours at 37ºC in a 96-well plate coated 
with Matrigel (R&D Systems, Minneapolis, MN). The 
formation of capillary-like structures was captured under 
a light microscope. The formed tubes, which represented 
the degree of in vitro angiogenesis, were scanned and 
quantitated in five low-power fields (100x).
Nude mice xenograft studies.
All experimental procedures involving animals 
were performed in accordance with the Guide for the 
Care and Use of Laboratory Animals (NIH publications 
86-23, revised 1985), and according to the institutional 
ethical guidelines for animal experiments. For the 
subcutaneous xenograft model, PLC8024 cells (6x106) 
that were transducted with NC or shRNA specific for 
EIF5A2 were suspended in 200μl 1xPBS and then injected 
subcutaneously into the right side the posterior flank of 
BALB/c athymic nude mice at 5 weeks of age. Twelve 
nude mice were injected and tumor growth was examined 
over the course of 35 days. Treatment with 5-FU in 
nude mice were performed as previously described [40]. 
In some experiments, local tumor blood flow was 
measured with a Laser Doppler imager (Perimed AB, 
Box564, SE-17526, Stockholm, Sweden) on anesthetized 
mice as previously described [41].
Dual-luciferase assay.
Liver cells grown in a 24-well plate were 
cotransfected with 400ng of either pGL3-MMP2-
promoter-WT or pGL3-MMP2-∆AP-1 or pMIR-MMP2-
3’UTR and 10ng of pRL-TK (Promega, Madison, WI) and 
used for luciferase assays 48 h after transfection according 
to standard protocol. Each experiment was performed 
independently in triplicate.
Gelatin zymography assay.
Liver cells were incubated in serum-free DMEM 
for 24h. The TCM was collected, concentrated (Microcon 
10K; Millipore Co., Bedford, MA), and mixed with 2X 
non-reducing sample buffer and directly applied to a 
10% acrylamide gel containing 1 mg/ml gelatin. After 
electrophoresis, the gel was soaked in 2.5% Triton X-100 
to remove SDS and then incubated at 37°C overnight 
in the development buffer, followed by staining with 
Coomassie Brilliant Blue R-250.
Immunofluorescence (IF) staining.
Tumor tissue sections were deparaffinized and 
rehydrated through graded alcohol, immersed in 3% 
hydrogen peroxide to block endogenous peroxidase activity, 
and subjected to antigen retrieval by microwaving and boiled 
in EDTA buffer (pH = 8). Subsequently, the slides were 
incubated with anti-mouse/human CD34 and collagen IV 
overnight at 4°C. After washing, slides underwent incubation 
with fluorescence-conjugated secondary antibodies. Finally, 
slides were washed and mounted with DAPI (Vector 
Laboratories, Burlingame, CA) before imaging using a 
fluorescence microscope (Leica, Deerfield, IL).
Table 5. Primer sequences used for cloning.
Name Sequence
MMP2-p-F 5’-AGTAGATCT TTCTCCAGTGCCTCTTGCTG-3’
MMP2 -p-∆AP1-F 5’-AGTAGATCTGAAGTCAGGCGTTCCCAAC-3’
MMP2-p-R 5’-AGTAAGCTT AGGTCCTGGCAATCCCTTTG-3’
MMP2-UTR-F 5’-TGAACTAGTCACTGCCTTCGATACACCG-3’
MMP2-UTR-R 5’-TCCAAGCTTCACGTGAAAAGTGCCTTGC-3’
MMP2-F 5’-TTACTCGAGATGGAGGCGCTAATGGCC-3’
MMP2-R 5’-TATACGCGTTCAGCAGCCTAGCCAGTC-3’
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Tumor hypoxia.
Hypoxia in tumors was detected by the formation 
of pimonidazole adducts as previously described [42, 43].
Tumor perfusion assay.
Tumor vessel perfusion assays were performed as 
previously described [44]. Briefly, tumor-bearing mice 
were injected via the tail vein with Texas Red-conjugated 
Dextran at 100mg/kg (Sigma-Aldrich, Shanghai, China). 
After 3h, mice were injected with FITC-Lectin (Vector 
Laboratories, Burlingame, U.S.A.) at 10mg/kg. After ten 
minutes, mice were perfused with saline and tumors were 
harvested for cryosection and examined by fluorescence 
microscopy.
Transmission electron microscope (TEM).
Excised tumor tissues were fixed immediately in 2% 
paraformaldehyde and 2.5% gluteraldehyde, after which 
tissues were cut into small pieces (0.5-1.0mm3) and fixed 
overnight at 4°C, then postfixed in 1% osmium tetroxide, 
dehydrated and embedded according to standard protocol. 
Ultra-thin sections were cut and stained with lead citrate 
and uranyl acetate and examined with a transmission 
electron microscope (Tecnai G2 Spirit Twin, FEI, U.S.A.).
Immunohistochemistry (IHC) and selection of 
cut-point score.
TMA slides were incubated respectively with 
anti-EIF5A2 (kindly provide by Dr Geng-Xi Hu, 1:100 
dilution), anti-MMP2 and anti-CD34 (Santa Cruz, CA, 
1:100 dilution). Immunostaining was performed using 
the Envision System with diaminobenzidine (Dako, 
Glostrup, Denmark). A negative control was obtained by 
replacing the primary antibody with a normal IgG. Known 
immunostaining positive cases were used as positive 
controls.
The immunoreactivity for EIF5A2 and MMP2 were 
scored in a semiquantitative method. In brief, each TMA 
spot was assigned an intensity score from 0–3 (I0, I1–3). 
Then, the proportion of tumor cells of that intensity was 
divided by the total number of tumor cells and recorded 
in 5% increments from 0 to 100 (P0, P1–3). The final H 
score (range 0–300) was determined by adding the sum of 
the scores obtained for each intensity and the proportion 
of the area stained (H score = [I1×P1]+[I2×P2]+[I3×P3]). 
The microvessel density (MVD) in tumor tissues was 
evaluated by IHC staining for CD34. Any discrete cluster 
or single cell stained for CD34 was counted as one 
microvessel. The scores were assessed by two independent 
pathologists (Cai MY and Xie D) who were blinded to the 
clinicopathological data.
X-tile plots were used for assessment of EIF5A2, 
MMP2 and CD34 expression and optimization of cut-point 
based on outcome. The X-tile plots allowed determination 
of an optimal cutoff value while correcting for the use 
of minimum P statistics by Miller-Siegmund P-value 
correction [45, 46].
Statistical analysis.
For survival analysis, the optimal cut-point for 
EIF5A2 expression was obtained using X-tile software 
version 3.6.1 (Yale University School of Medicine, New 
Haven, CT), as described previously [45]. The correlation 
between EIF5A2 expression and clinicopathological 
features of HCC patients was analyzed using the χ2 test 
or Fisher’s exact test. For univariate survival analysis, 
survival curves were obtained using the Kaplan-Meier 
method. The Cox proportional hazards regression model 
was performed for multivariate survival analysis. The 
independent Student’s t test was performed to analyze the 
statistical significance between two preselected groups. 
P values of less than 0.05 were considered statistically 
significant.
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